You're not imagining it. And you're not stuck with it.

Usually by pattern rather than by a single test. Perimenopause commonly begins in your forties and can run four to eight years before your periods stop altogether. Hormone levels swing week to week during that stretch, so one blood draw can look reassuringly normal while you feel anything but — which is exactly how so many women get told nothing is wrong. We test broadly, read the results against your symptoms rather than in isolation, and re-test over time. The picture almost always becomes clear; it just doesn't come from a single number.

Those headlines came from the Women's Health Initiative in 2002, and they changed practice overnight — for a generation of women who, it turns out, were mostly not the women in the study. The average participant was 63 and more than a decade past menopause, and the formulations used are not the ones we reach for now. Twenty years of reanalysis has produced a much clearer picture: for healthy women who begin therapy before about 60, or within roughly ten years of menopause, the balance sits firmly in favor of treating. It also showed that route matters enormously — estrogen that enters the body without passing through the liver first does not carry the clot signal that swallowed estrogen does. That is why the modern answer to the safety question is not a disclaimer. It is a protocol.

Sooner than most women expect for the symptoms that bother them most. Hot flashes and night sweats typically begin easing within the first two to six weeks, and sleep usually improves alongside them — which by itself tends to lift mood, patience and clarity within the same window. Vaginal and urinary symptoms respond well but on a slower curve, often eight to twelve weeks, and they respond to local treatment particularly reliably. Body composition and strength shift over three to six months, and bone density gains accrue across the first year. We re-test at six to eight weeks and adjust, so the first plan is a starting point rather than a verdict.

Possibly for systemic therapy, and we will be straight with you about it — but that rarely means there is nothing to do. The evidence supports starting within about ten years of menopause or before 60, and beginning much later shifts the calculation, particularly around cardiovascular risk. What does not change with age is local vaginal estrogen, which has a very different and much more favorable profile at any age and is remarkably effective for dryness, discomfort and recurrent urinary infections. Beyond that, a great deal of what drives how you feel at 65 is metabolic and cardiovascular rather than hormonal, and that is entirely addressable. The goal is to find the right answer for you, not to fit you to one treatment.

Yes — bioidentical simply means the molecule is structurally identical to what your body makes, and that is what we prescribe. The word gets used loosely in marketing, so here is exactly where we stand. Your progesterone is FDA-approved micronized progesterone, taken orally. Estradiol and, where appropriate, testosterone are most often delivered as subcutaneous pellets, which are compounded rather than FDA-approved — there is no FDA-approved estradiol pellet, and no testosterone product approved for women in the United States at all. We think that trade-off is worth it for the delivery advantages, and we would rather tell you it exists than let you discover it later. What makes it work safely is measurement: we check levels rather than assuming them.

Because in practice they are the version women actually stay on. A cream has to be applied every single day, often somewhere women would rather not apply it, and how much crosses the skin varies with where it went and what happened afterwards. Patches have to stay stuck — through heat, exercise, sun and swimming — and when the adhesive gives up mid-week the dose goes with it. Both have also been subject to supply disruption. A pellet is placed in a few minutes in the office, releases steadily for months, cannot be forgotten, cannot fall off, and cannot transfer to a partner or a grandchild. Dr. Chris pursued this deliberately: he completed the Hormonal Health Institute’s CME-accredited BHRT masterclass for clinicians and holds its clinician certification, on top of forty-four years of procedural practice. The known criticism of pellets is that they can overshoot physiologic levels — which is a dosing and monitoring problem, and it is exactly why we measure your levels rather than assume them, and why we start conservatively and adjust at the next placement.

It has a real but narrower role than the internet suggests. The best evidence supports low-dose testosterone for postmenopausal women with genuinely distressing low sexual desire, once other contributors have been addressed. Worth knowing: there is currently no testosterone product approved by the FDA specifically for women in the United States, so any use is off-label and calls for careful dosing and monitoring — which is precisely why it belongs with a physician who measures rather than a clinic that dispenses. Done properly, at female physiologic doses with levels tracked, it is a useful tool. Done at male-range doses, which is a genuine pattern in this industry, it causes problems that take a long time to undo.

Often it isn't, and if you have a gynecologist actively engaged in menopause care, that is a good thing and we will tell you so. What we add is depth and continuity: a comprehensive metabolic, thyroid, bone and cardiovascular panel drawn alongside your hormones, appointments long enough to actually work through it, and a physician tracking the same numbers across years rather than at an annual visit. Menopause sits at the intersection of hormones, metabolism, bone and cardiovascular risk, and it rewards being looked at as one picture by one person.